Hepatitis C virus (HCV) remains a global public health problem even though more than 95%
of infections can be cured by treatment with direct-acting antiviral agents. Resolution of …

Known for its high genetic diversity and variation in genotypic presence in different regions
of the world, hepatitis C virus (HCV) is estimated to infect about 71 million people globally …

In China, few molecular epidemiological data on hepatitis C virus (HCV) are available and
all previous studies were limited by small sample sizes or specific population characteristics …

Objective Very few cost-utility analyses have either evaluated direct-acting antivirals (DAAs)
on hepatitis C virus (HCV) genotype 6 patients or undertaken societal perspective. Recently …

Background: World Health Organization has called for research into predictive factors for
selecting persons who could be successfully treated with shorter durations of direct-acting …

Background Genotype 6 is the most genetically diverse lineage of hepatitis C virus, and it
predominates in Vietnam. It can be treated with sofosbuvir with daclatasvir (SOF/DCV), the …

Background Hepatitis C virus (HCV) genotype 6 is the commonest cause of chronic hepatitis
C infection in much of southeast Asia, but data on the effectiveness of direct-acting antiviral …

The desired performance of nucleic acid testing (NAT) may vary if used for disease
diagnosis or for the evaluation of the therapeutic efficacy of a treatment, although in most …

Hepatitis C virus (HCV) is the leading cause of chronic liver disease. HCV genotypes and
subtypes are important predictors of disease progression and antiviral treatment response …

Introduction: The measurement of hepatitis C virus (HCV) RNA is a test that requires high
cost, advanced technique, and qualified personnel. Diagnosis and treatment of patients may …